Co-Diagnostics, Inc. Regains NASDAQ Compliance and Expands Globally

Font: Financial Modeling Prep  • Mar 16, 2026

Co-Diagnostics, Inc. (NASDAQ: CODX) Regains NASDAQ Compliance and Resumes Trading

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a patented platform for developing diagnostic tests, has regained compliance with NASDAQ listing requirements and resumed trading on The Nasdaq Capital Market effective March 11, 2026. The company received formal notice from Nasdaq on March 9, 2026, confirming compliance with all criteria, including the $1.00 minimum bid price rule. This resolves a prior listing compliance issue and enhances the company's capital markets position as it advances its Co-Dx PCR point-of-care platform toward market.

The company is actively expanding its global presence and intellectual property. Co-Diagnostics will participate in Medical Korea 2026 in Seoul, South Korea, from March 19-22, 2026, alongside the World Trade Center Utah, Utah Governor's Office of Economic Opportunity, BioUtah, and other leaders. Co-Dx will join a healthcare business roundtable on March 19 and deliver a presentation showcasing its Co-Dx PCR point-of-care platform and innovative diagnostic solutions. The event anticipates over 6,000 participants from more than 50 countries, offering strong networking potential.

Additionally, on March 12, 2026, the Japan Patent Office granted Japanese Patent No. 7797537, titled "Systems, Methods, and Apparatus for Automated Self-Contained Biological Analysis." This patent, initially registered on December 26, 2025, and filed under the Patent Cooperation Treaty (PCT), includes 34 claims and supports the Co-Dx PCR Pro® instrument, test cups, and other platform components. It follows a similar grant from the Australian Patent Office in 2025 and bolsters the company's international IP protection.

As of the latest available data (close on March 13, 2026), CODX stock closed at $2.80, reflecting a +3.75% increase. The day's trading ranged from a low of $2.55 to a high of $2.98. Over the past year, the stock has ranged from a low of approximately $2.05 to a high of $46.50. Market capitalization is approximately $5.87 million, with trading volume of 1,105,301 shares on March 13, 2026. The company trades on NASDAQ, following the resumption of listing.

This positions Co-Diagnostics as an emerging player in molecular diagnostics, with ongoing focus on clinical studies, regulatory pathways, and global expansion for its point-of-care technologies.